- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05845255
Validation of the Mjn-SERAS Performance
Validation of the Mjn-SERAS Solution for the Detection and Prediction of Epileptic Seizures in Epilepsy Drug-resistant Patients, During Their Day-to-day Activity, to Find Out the Impact in a Normalised Environment.
A prospective, multicentre, postmarketing, pilot clinical study is proposed to validate in the day-to-day life a medical device (mjn-SERAS), which has already been validated and certified in Europe.
The patient's characteristics about epilepsy, drug-resistant epilepsy, inclusion and exclusion criteria for the study.
This new validation will take place in the participant's normalised environment, in individuals between 12 and 65 years of age, of both sexes with a diagnosis of drug-resistant epilepsy to determine the impact of the mjn-SERAS on the early detection of epileptic seizures and the generation of a pre-seizure alert with a time window of a minimum of 1 minute.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective, multicentre, postmarketing, pilot clinical study is proposed to validate in the day-to-day life a medical device (mjn-SERAS), which has already been validated and certified in Europe by BSI(British Standard Institution) Group (CE2797) notified body CE 685187. The study will be performed in Spain, Germany and UK (United Kingdom).
The patient's characteristics about epilepsy, drug-resistant epilepsy, inclusion and exclusion criteria for the study, considering the same classification in ICD-10 (International Statistical Classification of Diseases) for Spain and NHS(National Health Services) in the UK, and ICD(International Classification of Diseases) ICD-10-GM for Germany, and the target population where the researchers will study the solution are the same for the 3 countries, so all are considering the international standards from ILAE(International League Against Epilepsy) 2017 classification, including German Society for Epileptology and ILAE British Chapter, defined in next sections.
This new validation will take place in the participant's normalised environment, in individuals between 12 and 65 years of age, of both sexes with a diagnosis of drug-resistant epilepsy, according to CE mark considerations and intended use, which will make it possible to determine the impact of the mjn-SERAS on the early detection of epileptic seizures and the generation of a pre-seizure alert with a time window of a minimum of 1 minute. The sensitivity, specificity and accuracy of the medical device solution in the studied environment will also be calculated.
The pre-determined sample size determined is an n=130 exposed individuals who meet the inclusion criteria. The patients will be recruited in Spain, Germany, and UK. It is not a controlled and randomised design, the pre-post assessment for each patient will allow to compare data before and after the use of the mjn-SERAS solution, creating a baseline initially and a final evaluation.
The method applied during the study consists of using a mjn-SERAS, software application with the earpiece of the external auditory canal customised for the patient.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: David Blánquez, Engineer
- Phone Number: +34652918809
- Email: david@mjn.cat
Study Contact Backup
- Name: Fernando Atienza, QM
- Phone Number: +34 645 86 25 25
- Email: fatienza@mjn.cat
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
According to the 2005 World Health Organization (WHO) report, epilepsy is a disease that affects about 1% of the population worldwide. 30% of patients are resistant to antiepileptic treatment.
It is proposed a clinical trial for people from 12 to 65 years, in a day-to-day activity outside hospital. It will be a prospective analysis of 130 subjects with a clinical diagnosis of epilepsy patients whose clinical semiology of their epilepsy is considered to be of interest for the validation of this study.
Description
Inclusion Criteria:
Clinical criteria:
- Confirmed diagnosis of drug-resistant epilepsy, with focal, generalized or focal -generalized seizures, according to international standards from ILAE 2017 classification (link), who will be evaluated by a specialised epilepsy unit and who are expected to have seizures.
- The video-EEG records of patients must have epileptic seizures counted and recorded by specialised clinical personnel through accepted and contrasted gold-standard systems*3.
- Patients with a clinical history and previous video-EEG records that allows certainty about the diagnosis and characteristics of the participant's epilepsy.
- Precise semiological information on the patients included.
- Patients with both sides localisation will be accepted, and the wearable device will be placed in the side that is most evident the origin of the seizures, to be placed as near as possible to the focal point.
- Presence of more than 10 seizures per year, from tonic, tonic-clonic, clonic or atonic seizures, reported by the patients/caregivers or assessed by the neurologist through the patient history.
Patients included in ICD-10 classification as G40 (link) with electroclinical manifestation of seizures
▪ Technological criteria:
- Ability to navigate in Android operating system. Patients with lack of Android mobile phone will be provided with device and/or training as appropriate.
Exclusion Criteria:
- Presence of psychogenic seizures.
- Psychiatric, neurological, or systemic disorders that the researcher believes could affect the realisation and interpretation of the results.
- Presence of more than 10 seizures per day on a habitual basis.
- Presence of epilepsia partialis continua
- Patients with legal representative
- Patients with only absence seizures, myoclonic seizures or epileptic spasms.
Patients included in ICD-10 classification
- G40.0 Localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset
- G40.4 Other generalized epilepsy and epileptic syndromes
- G40.5 Special epileptic syndromes
- G40.9 Epilepsy, unspecified
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of life index of patients with epilepsy
Time Frame: 12 months
|
1. To assess the quality of life of patients with epilepsy and the degree of health perceived by the patient and caregiver when using the mjn-SERAS solution to generate alarms when the possibility of a new epileptic seizure is anticipated.
|
12 months
|
Change in quality of life 5D of patients with epilepsy
Time Frame: 12 months
|
1. To assess the quality of life of patients with epilepsy and the degree of health perceived by the patient and caregiver when using the mjn-SERAS solution to generate alarms when the possibility of a new epileptic seizure is anticipated.
|
12 months
|
Patient's safety
Time Frame: 12 months
|
2. To assess the evolution of the patient's safety related with accidents in patients with epilepsy when using the mjn-SERAS solution.
|
12 months
|
Change in mental and emotional well-being
Time Frame: 12 months
|
3. To analyse the change in the mental and emotional well-being of patients with epilepsy who regularly use the mjn-SERAS solution.
|
12 months
|
Change in quality of life social relationships
Time Frame: 12 months
|
4. To analyse the evolution of social relationships indicators in different areas of personal development in patients with epilepsy who regularly use the MJN SERAS solution.
|
12 months
|
Change in social relationships and physical functioning
Time Frame: 12 months
|
4. To analyse the evolution of social relationships indicators in different areas of personal development in patients with epilepsy who regularly use the MJN SERAS solution.
|
12 months
|
Change in social relationships and role limitations
Time Frame: 12 months
|
4. To analyse the evolution of social relationships indicators in different areas of personal development in patients with epilepsy who regularly use the MJN SERAS solution.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in health resources utilization
Time Frame: 12 months
|
5. Assess the impact on health care resources utilization (including associated sick leave) as a result of the ability to take preventive measures ahead of a seizure.
Healthcare resources*1: Health care resources related to seizures are number of visits to general practitioner, specialists and emergency room, hospitalizations, outpatient procedures, hours of formal care and unscheduled visits or any other use of resources. |
12 months
|
Seizure correlation for patients report
Time Frame: 12 months
|
6a. Measure the correlation between the warning alarms of mjn-SERAS solution and the report provided by the patient/caregiver/families regarding the presence of clinically significant epileptic seizures, as well as to analyse the algorithm for evaluating the possibility of seizure presentation and its subsequent correlation and agreement with the clinical phase.
|
12 months
|
Seizure correlation for patient knowledge
Time Frame: 12 months
|
6b. Measure the correlation between the warning alarms of mjn-SERAS solution and the report provided by the patient/caregiver/families, as well as to analyse the algorithm for evaluating the possibility of seizure presentation and its subsequent correlation and agreement with the clinical phase.
|
12 months
|
Medical device performance
Time Frame: 12 months
|
7. To analyse and validate the mjn-SERAS solution in the standard patient environment as a system for assessing the possibility of epileptic seizures, generating an alarm prior to the clinical evidence or manifestation of a seizure to avoid accidents*2
Medical device performance*3: "Performance of a clinical function, other than that related to basic safety, where loss or degradation beyond the limits specified by the manufacturer results in an unacceptable risk." |
12 months
|
Device safety evaluation with questionnaire
Time Frame: 12 months
|
8. To analyse the usability and device-related safety of the digital solution in normal life conditions, normalised environment, with a daily use by the patient.
|
12 months
|
Device safety evaluation and adverse effects
Time Frame: 12 months
|
8. To analyse the usability and device-related safety of the digital solution in normal life conditions, normalised environment, with a daily use by the patient.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specification of patients for the use of mjn-SERAS solution
Time Frame: 12 months
|
9. The creation of a database that allows the relation of semiological variables, location of the epileptic focus and the specific results of the mjn-SERAS solution in each of the cases.
|
12 months
|
Specification of seizures for AI(Artificial Intelligence) algorithm
Time Frame: 12 months
|
10. To analyse the results of the mjn-SERAS solution according to the different crisis semiology.
|
12 months
|
Knowledge dissemination to doctors
Time Frame: 12 months
|
11. To increase the knowledge of healthcare professionals on the patient and the disease, by way of accessing EEG records and seizures to make better decisions on treatment and therapies .
|
12 months
|
Knowledge dissemination to scientific community
Time Frame: 12 months
|
11. To increase the knowledge of healthcare professionals on the patient and the disease, by way of accessing EEG records and seizures to make better decisions on treatment and therapies .
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Antonio Gil-Nagel, MD PhD, Department of Neuroscience Clinica Corachan & Synaptia Health Projects
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 04_SERAS_Home_RWD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteCompletedProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life